| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
|
Medicine details |
|
| Medicine name | alirocumab (Praluent®) |
| Formulation | 75 mg/ml, 150 mg/ml, 300 mg/2 ml solution for injection |
| Reference number | 1746 |
| Indication | Treatment in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. Treatment of adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated |
| Company | Sanofi-Aventis Ltd |
| BNF chapter | Cardiovascular system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 18/08/2015 |
| NICE guidance | TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |